2014

China Jo-Jo Drugstores Announces Fiscal 2014 Second Quarter Financial Results

BEIJING, Nov. 14, 2013 /PRNewswire/ --

Fiscal Year 2014 Second Quarter Highlights:

  • In three months online sales contributed $1.6 million in revenue, an increase of 85.6% from the prior period
  • Retail sales, approximately 65.6% of total revenue for the three months ended September 30, 2013, increased by $0.6 million or 5.3% to $11.1 million compared with the same period last year
  • Cost of goods sold in the second quarter decreased to $13.9 million, down 40.2% compared with the same period last year
  • Gross margin increased quarter over quarter from 12.8% to 17.5%
  • Net loss was $0.55 million in the second quarter, losses narrowed 64.3% compared with the same period last year
  • Diluted and basic loss per share was $0.04

China Jo-Jo Drugstores, Inc. (CJJD) (the "Company"), a retail and wholesale distributor of pharmaceutical and other healthcare products in China, today announced earnings results for the three months ended September 30, 2013. As previously announced, the Company will hold a conference call at 8:00 A.M. Eastern Time on Friday November 15. Please see below for dial-in information.

Mr. Lei Liu, the Company's Chairman and CEO, stated, "Due to the closure of 16 stores in the past calendar year, our drugstore sales declined slightly quarter over quarter. However, our same-store sales grew. Looking forward, we will continue to focus on our competitive advantages in the retail drugstore segment: hiring additional clinic staff to better advise on drug selection, looking to open additional clinics next to our drugstores, and stocking each store location to better cater to its neighborhood. Additionally, our online pharmacy grew steadily quarter over quarter, reflecting our efforts in collaborating with large B2C vendors, identifying products suitable for online customers, and controlling costs. Nevertheless, retail profit margin decreased slightly from the same period last year as we were forced by government price control to adjust prices." As of November 14, 2013, the Company operated 51 pharmacies, including five in Shanghai.

Mr. Liu continued, "Since the third quarter of fiscal 2013, we have stopped low margin sales in our wholesale segment and are focusing on profitability over sales volume. As a result, our sales volume declined while gross profit margin increased significantly. Although this strategy may impact our ability to achieve first-tier distributor status, we believe that this approach is critical for our overall operations going forward."

"For the remaining of fiscal 2014, we are looking to stabilize and grow our revenue primarily through our retail operation, and we will continue our wholesale operations with an eye on bottom line results," concluded Mr. Liu.

Balance Sheet Highlights

As of September 30, 2013, the Company had $6.3 million of cash, $70.3 million in total assets and $32.4 million in total liabilities.

Fiscal Year 2014 Second Quarter Results

Comparison of three months ended September 30, 2013 and 2012

The following table summarizes our results of operations for the three months ended September 30, 2013 and 2012:

 


Three months ended September 30,


2013


2012


Amount


Percentage

of total

revenue


Amount


Percentage

of total

revenue

Revenue

$

16,855,421



100.0%


$

26,665,114



100.0%

Gross profit

$

2,948,403



17.5%


$

3,422,197



12.8%

Selling expenses

$

2,979,131



17.7%


$

2,102,621



7.9%

General and administrative expenses

$

491,981



2.9%


$

1,310,313



4.9%

(Loss) income from operations

$

(522,709)



(3.1) %


$

9,263



0.0%

Other income (expense), net

$

37,021



0.2%


$

(90,332)



(0.3)%

Goodwill impairment loss

$

-



-%


$

(1,473,606)



(5.5)%

Change in fair value of purchase option derivative liability

$

(21,049)



(0.1)%


$

25,905



0.1%

Income tax expense

$

39,589



0.2%


$

10



0.0%

Net loss attributable to controlling interest

$

(546,590)



(3.2)%


$

(1,528,449)



(5.7)%

Net loss attributable to noncontrolling interest

$

(264)



(0.0)%


$

(331)



(0.0)%

Revenue

Revenue decreased by $9,809,693  or 36.8% period over period, primarily due to decrease in our wholesale business, offset by slight increase in our retail business:


(1)

Wholesale revenue, which represented 34.4% of total revenue for the three months ended September 30, 2013, decreased by $10,364,687 or 64.1%. Such significant contraction resulted from ongoing implementation of our new wholesale strategy to focus on profitability rather than sales volume.  Thus, our wholesale profit margin increased from 2.5% to 18.6%. However, until we can achieve first-tier distributor status with more vendors, we will continue to have limited access to more lucrative sales channels such as hospitals, and do not expect our wholesale business to expand significantly in the immediate future.


(2)

Retail sales, which accounted for approximately 65.6% of total revenue for the three months ended September 30, 2013, increased by $554,994 or 5.3% to $11,052,942.  Same-store sales increased by approximately $66,080 or 0.7%, while online sales contributed approximately $1,596,950 in revenue, an increase of 85.6%.  The increase in same-store sales reflects implementation of key drugstore operational strategies such as promoting sale through our doctors and clinics, as well as modest economic growth in China.  Retail margin, however, fell from 26.0% to 22.7% due to price adjustments caused by government drug price control.  Our store count decreased to 51 as of September 30, 2013, from 65 a year ago.

 

Quarterly Revenue by Segment

The following table breaks down the revenue for our three business segments for the three months ended September 30, 2013 and 2012:






Three months ended September 30,






2013


2012






Amount


% of total revenue


Amount


% of total revenue


Variance by amount


% of change

Revenue from retail business












     Revenue from drugstores

$

9,455,992



56.1%


$

9,637,418



36.2%


$

(181,426)



(1.9)%

     Revenue from online sales


1,596,950



9.5%



860,530



3.2%



736,420



85.6%

          Sub-total of retail revenue


11,052,942



65.6%



10,497,948



39.4%



554,994



5.3%



















Revenue from wholesale business


5,802,479



34.4%



16,167,166



60.6%



(10,364,687)



(64.1) %

Revenue from farming business


-



-%



-



-%



-



N/A

Total revenue

$

16,855,421



100%


$

26,665,114



100%


$

(9,809,693)



(36.8) %

 

The revenue fluctuation period over period reflected the following combined factors:


(1)

Drugstore revenue decreased by $181,426 or 1.9% primarily from two factors. We closed 16 stores in the past calendar year.  Although these stores were underperforming, they nevertheless contributed approximately $380,000 in revenue.   We also opened two stores in Shanghai during the same period, which contributed approximately $20,000 in revenue.  Sales generated by in-store clinics and same store sales grew (despite budgetary control by government health insurance) by approximately $110,000 and $70,000, respectively,  although they were not sufficient to offset the effect of the store closures.


(2)

Wholesale revenue decreased by $10,364,687 or 64.1% as a result of our strategy to focus on profitability. Although we achieved our sales volume in the prior period quickly through competitive pricing, we incurred loss as result of low profit margin and rising overhead. Since the third quarter of fiscal 2013, we have ceased certain low margin sales and are focusing on profitability rather than sales volume.  Although this strategy may impact our ability to achieve first-tier distributor status, we believe that focusing on profitability rather than volume is critical for our overall operations going forward.


(3)

Online sales increased by $736,420 or 85.6%.  We have been working with business-to-consumer online vendors, including Taobao, by posting our products on their online platforms, which direct customers back to our website.  Such arrangement has exposed our online presence to a wider consumer base.  In addition, since the end of 2012, we have expended considerable efforts in identifying popular products that can drive sales.  As a result, we have seen steady growth in online sales.

 

Gross Profit

Gross profit decreased by $473,794 or 13.8% period over period primarily as a result of the contraction in wholesale business.  Gross margin increased period over period from 12.5% to 17.8% as a result of higher wholesale profit margin, offset by a lower retail profit margin.  The average gross margins for our three business segments are as follows:



Three months ended

September 30,




2013



2012


Average gross margin for retail business 



23.0%




26.6%


Average gross margin for wholesale business 



7.6%




3.9%


Average gross margin for farming business 



N/A




N/A


 

Retail gross margin decreased primarily due to price adjustments that we made. Some adjustments were made to comply with government price controls. Others were made to stay competitive with local community hospitals that are able to sell at or near cost as their pharmacies are indirectly subsidized through the government. We also adjusted prices to match or better other competitors' prices. Accordingly, overall retail gross profit margin decreased. 

Wholesale gross margin increased because we are now focused on profitability for this segment such as by selling high margin products.  By comparison, our drive to generate sales volume by selling very low margin products created the low gross margin a year ago.

Selling and Marketing Expenses

Sales and marketing expenses increased by $876,510 or 41.7% period over period.  The increase in absolute dollars is mainly due to membership rewards to commemorate Jiuzhou Pharmacy's ten-year anniversary in August and September 2013.  Such expenses as a percentage of revenue increased to 17.7% from 7.9% for the same period a year ago due to significantly lower wholesale revenue.  We expect sales and marketing expenses to be lower after the anniversary commemoration.

General and Administrative Expenses

General and administrative expenses decreased by $818,332 or 62.5% period over period.  Such expenses as a percentage of revenue decreased to 2.9% from 4.9% for the same period a year ago.   The decrease in absolute dollars as well as the percentage of revenue mainly reflects decrease in allowance for advances to suppliers. We expect future general and administrative expenses to be affected by allowance adjustments significantly.

(Loss) Income from Operations

As a result of lower revenue and lower gross profit margins, we had loss from operations of $522,709, as compared to income from operations of $9,263 a year ago.  Our operating margin for the three months ended September 30, 2013 and 2012 was (3.3)% and 0.0%, respectively.

Income Taxes 

Income tax expense increased by $39,579 period over period, as a result of higher taxable income from Jiuzhou Pharmacy.

Net Loss

As a result of the foregoing, net loss decreased by $981,859 period over period.

Comparison of six months ended September 30, 2013 and 2012

The following table summarizes our results of operations for the six months ended September 30, 2013 and 2012:


Six months ended September 30,


2013


2012


Amount


Percentage

of total

revenue


Amount


Percentage

of total

revenue

Revenue

$

32,191,940



100.0%


$

59,512,445



100.0%

Gross profit

$

6,549,572



20.3%


$

8,566,974



14.4%

Selling expenses

$

4,659,973



14.5%


$

3,960,845



6.7%

General and administrative expenses

$

3,132,799



9.7%


$

4,156,892



7.0%

(Loss) income from operations

$

(1,243,200)



(3.9)%


$

449,237



0.8%

Other income (expense), net

$

(90,332)



(0.3)%


$

8,367



0.0%

Goodwill impairment loss

$

-



-%


$

(1,473,606)



(2.5)%

Change in fair value of purchase option derivative liability

$

(8,384)



(0.0)%


$

25,747



0.0%

Income tax expense

$

79,109



0.2%


$

3,892



0.0%

Net loss attributable to controlling interest

$

(1,333,578)



(4.1)%


$

(993,562)



(1.7)%

Net loss attributable to noncontrolling interest

$

(507)



(0.0)%


$

(585)



(0.0)%

 

Revenue

Revenue decreased by $27,320,505 or 45.9% period over period, primarily due to decrease in our wholesale business, offset by slight increase in our retail business:


(1)

Wholesale revenue, which represented 31.8% of total revenue for the six months ended September 30, 2013, decreased by $27,309,341 or 72.8%. Such significant contraction resulted from ongoing implementation of our new wholesale strategy to focus on profitability rather than sales volume.  Thus, our wholesale profit margin increased from 2.5% to 18.6%. However, until we can achieve first-tier distributor status with more vendors, we will continue to have limited access to more lucrative sales channels such as hospitals, and do not expect our wholesale business to expand significantly in the immediate future


(2)

Retail sales, which accounted for approximately 68.2% of total revenue for the six months ended September 30, 2013, increased by $2,512,927 or 12.9% to $11,052,942. Same-store sales increased by approximately $1,066,343 or 6.2%, while online sales contributed approximately $2,865,592 in revenue, an increase of 102.1%.   The increase in same-store sales reflects implementation of key drugstore operational strategies such as promoting sale through our doctors and clinics, as well as modest economic growth in China.  Retail margin, however, fell from 26.3% to 24.1% due to price adjustments caused by government drug price control.  Our store count decreased to 51 as of September 30, 2013, from 65 a year ago.

 

Six-Month Revenue by Segment

The following table breaks down the revenue for our three business segments for the six months ended September 30, 2013 and 2012:


Six months ended September 30,






2013


2012






Amount


% of total revenue


Amount


% of total revenue


Variance by amount


% of change

Revenue from retail business












     Revenue from drugstores

$

19,099,740



59.3%


$

18,034,415



30.3%


$

1,065,325



5.9%

     Revenue from online sales


2,865,592



8.9%



1,417,990



2.4%



1,447,602



102.1%

          Sub-total of retail revenue


21,965,332



68.2%



19,452,405



32.7%



2,512,927



12.9%



















Revenue from wholesale business


10,226,608



31.8%



37,535,949



63.1%



(27,309,341)



(72.8)%

Revenue from farming business


-



-%



2,524,091



4.2%



(2,524,091)



(100.0)%

Total revenue

$

32,191,940



100%


$

59,512,445



100.0%


$

(27,320,505)



(45.9)%

 

The revenue fluctuation period over period reflected the following combined factors:


(1)

Drugstore revenue increased by $1,065,325 or 5.9% period over period, primarily caused by two factors.  First, same stores sales increased by approximately $1,070,000, including modest increase in sales covered by insurance.  Second, sales attributable to our clinics and from two new stores in Shanghai contributed approximately $680,000 and $40,000 to revenue, respectively.  On the other hand, we closed 16 stores in the past calendar year.  Although these stores were underperforming, they nevertheless contributed approximately $720,000 in revenue.


(2)

Wholesale revenue decreased by $27,309,341 or 72.8% as a result of our strategy to focus on profitability. Although we achieved our sales volume in the prior period quickly through competitive pricing, we incurred loss as result of low profit margin and rising overhead. Since our third fiscal quarter of fiscal 2013, we have ceased certain low margin sales and are focusing on profitability rather than sales volume.  Although this strategy may impact our ability to achieve first-tier distributor status, we believe that focusing on profitability rather than volume is critical for our overall operations going forward.


(3)

Online sales increased by $1,447,602 or 102.1% period over period.  We have been working with business-to-consumer online vendors, including Taobao, by posting our products on their online platforms, which direct customers back to our website.  Such arrangement has exposed our online presence to a wider consumer base.  In addition, since the end of 2012, we have expended considerable efforts in identifying popular products that can drive sales.  As a result, we have seen steady growth in online sales.

 

Gross Profit

Gross profit decreased by $2,017,402 or 23.5% period over period primarily as a result of the contraction in wholesale business.  Gross margin increased period over period from 14.4% to 20.3% as a result of higher wholesale profit margin, offset by a lower retail profit margin.  The average gross margins for our three business segments are as follows:



Six months ended

September 30,




2013



2012


Average gross margin for retail business 



24.3%




26.3%


Average gross margin for wholesale business 



12.4%




3.0%


Average gross margin for farming business 



N/A




90.9%


 

Retail gross margin decreased primarily due to price adjustments that we made. Some adjustments were made to comply with government price controls. Others were made to stay competitive with local community hospitals that are able to sell at or near cost as their pharmacies are indirectly subsidized through the government. We also adjusted prices to match or better other competitors' prices. Accordingly, overall retail gross profit margin decreased. 

Wholesale gross margin increased because we are now focused on profitability for this segment such as by selling high margin products.  By comparison, our drive to generate sales volume by selling very low margin products created the low gross margin a year ago.

Selling and Marketing Expenses

Sales and marketing expenses increased by $699,128 or 17.7% period over period.  The increase in absolute dollars is mainly due to membership rewards to commemorate Jiuzhou Pharmacy's ten-year anniversary in August and September 2013.  Such expenses as a percentage of revenue increased to 14.5% from 6.7% for the same period a year ago due to significantly lower wholesale revenue.  We expect future sales and marketing expenses to be lower after the anniversary commemoration.

General and Administrative Expenses

General and administrative expenses decreased by $1,024,093 or 24.6% period over period.  Such expenses as a percentage of revenue increased to 9.7% from 7.0% for the same period a year ago.   The significant decrease in absolute dollars mainly reflects decrease in allowance for advances to suppliers. The increase in percentage of revenue is mainly a result of a lower overall revenue base for the six months ended September 30, 2013. We expect future general and administrative expenses to be affected by allowance adjustments significantly.

(Loss) Income from Operations

As a result of lower revenue and lower gross margins, income from operations decreased by $1,692,437 or 376.7% period over period.  Operating margin for the six months ended September 30, 2013 and 2012 was (3.9)% and 0.8%, respectively.

Income Taxes 

Income tax expense increased by $75,217 period over period, as a result of higher taxable income from Jiuzhou Pharmacy.

Net Income

As a result of the foregoing, net income decreased by $340,016 period over period.

Conference Call Information

As previously announced, the Company will host a conference call to discuss its fiscal year 2014 first quarter results on Friday November 15, 2013 at 8 a.m. Eastern Time. To participate in the conference call, please dial 1-888-846-5003 from North America. International participants can access the call by dialing 1-480-629-9586. A live audio webcast of this conference call will be available under the Investor Relations section of the Company's website at http://www.chinajojodrugstores.com. A replay of the call will be available beginning the same day at approximately 11 a.m. Eastern Time by dialing 1-877-870-5176 or -1-858-384-5517 with pin #4651164. The replay will also be available on the company website.

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its subsidiaries and contractually controlled affiliates, is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. As of September 30, 2013, the Company had 51 retail pharmacies in Hangzhou and Shanghai.

Forward Looking Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

Contact:

China Jo-Jo Drugstores, Inc.
Ming Zhao, Chief Financial Officer
561-372-5555
frank.zhao@jojodrugstores.com


 

See Accompanying Tables

CHINA JO-JO DRUGSTORES, INC AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)



September 30,



March 31,



2013



2013







A S S E T S












CURRENT ASSETS






Cash


$

6,296,715



$

4,524,094

Trade accounts receivable, net



12,691,630




12,978,808

Inventories



12,167,632




8,586,999

Other receivables, net



425,902




157,849

Advances to suppliers, net



11,070,649




15,523,034

Restricted cash



1,964,313




2,162,837

Other current assets



2,140,802




1,221,499

Total current assets



46,757,643




45,155,120









PROPERTY AND EQUIPMENT, net



12,712,963




13,288,652









OTHER ASSETS








Long term deposits



4,184,317




2,760,665

Other noncurrent assets



5,460,500




5,431,326

Intangible assets, net



1,149,981




1,202,258

Total other assets



10,794,798




9,394,249









Total assets


$

70,265,404



$

67,838,021









L I A B I L I T I E S    A N D    S T O C K H O L D E R S'   E Q U I T Y
















CURRENT LIABILITIES








Short-term loan payable


$

163,000



$

-

Accounts payable, trade



19,455,279




13,780,211

Notes payable



6,547,710




7,186,453

Other payables



1,429,961




1,327,454

Other payables - related parties



2,104,735




1,224,417

Customer deposits



1,989,967




4,828,293

Taxes payable



379,981




371,633

Accrued liabilities



242,843




956,342

Total current liabilities



32,313,476




29,674,803









Purchase option derivative liability



60,043




15,609

Total liabilities



32,373,519




29,690,412









COMMITMENTS AND CONTINGENCIES
















STOCKHOLDERS' EQUITY








Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued
            and outstanding as of September 30, 2013 and March 31, 2013



-




-

Common stock; $0.001 par value; 250,000,000 shares authorized;  13,609,002 
            shares issued and outstanding as of September 30, 2013 and March 31, 2013



13,609




13,609

Additional paid-in capital



16,668,548




16,609,747

Statutory reserves



1,309,109




1,309,109

Retained earnings



15,761,791




17,095,369

Accumulated other comprehensive income



4,141,259




3,121,654

Total stockholders' equity



37,894,316




38,149,488









Noncontrolling interests



(2,431)




(1,879)

Total equity



37,891,885




38,147,609









Total liabilities and stockholders' equity


$

70,265,404



$

67,838,021


 

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


For the three months

ended September 30,



For the six months

ended September 30,


2013



2012



2013



2012

REVENUES, NET


$

16,855,421



$

26,665,114



$

32,191,940



$

59,512,445

















COST OF GOODS SOLD



13,907,018




23,242,917




25,642,368




50,945,471

















GROSS PROFIT



2,948,403




3,422,197




6,549,572




8,566,974

















SELLING EXPENSES



2,979,131




2,102,621




4,659,973




3,960,845

GENERAL AND ADMINISTRATIVE EXPENSES



491,981




1,310,313




3,132,799




4,156,892

TOTAL OPERATING EXPENSES



3,471,112




3,412,934




7,792,772




8,117,737

















(LOSS) INCOME FROM OPERATIONS



(522,709)




9,263




(1,243,200)




449,237

















OTHER INCOME (LOSS), NET



37,021




(90,332)




(3,392)




8,367

GOODWILL IMPAIRMENT LOSS



-




(1,473,606)




-




(1,473,606)

CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES



(21,049)




25,905




(8,384)




25,747

















LOSS BEFORE INCOME TAXES



(506,737)




(1,528,770)




(1,254,976)




(990,255)

















PROVISION FOR INCOME TAXES



39,589




10




79,109




3,892

















NET LOSS



(546,326)




(1,528,780)




(1,334,085)




(994,147)

















ADD: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST



264




331




507




585

















NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.



(546,062)




(1,528,449)




(1,333,578)




(993,562)

















OTHER COMPREHENSIVE INCOME
















Foreign currency translation adjustments



259,814




52,538




1,019,605




107,547

















COMPREHENSIVE LOSS


$

(286,248)



$

(1,475,911)



$

(313,973)



$

(886,015)

















WEIGHTED AVERAGE NUMBER OF SHARES:
















Basic



13,609,003




13,588,569




13,609,003




13,575,550

Diluted



13,609,003




13,588,569




13,609,003




13,575,550

















LOSSES PER SHARES:
















Basic


$

(0.04)



$

(0.11)



$

(0.10)



$

(0.07)

Diluted


$

(0.04)



$

(0.11)



$

(0.10)



$

(0.07)


 

 

 

 

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)




Six months ended

September 30,




2013



2012


CASH FLOWS FROM OPERATING ACTIVITIES:







Net loss


$

(1,334,085)



$

(994,147)


Adjustments to reconcile net (loss) income to net cash provided by (used in)

   operating activities:









  Depreciation and amortization



1,140,586




1,295,175


  Stock compensation



58,801




97,236


  Bad debt write-off and provision



(747,930)




834,772


  Goodwill Impairment



-




1,473,606


  Change in fair value of purchase option derivative liability



8,384




(25,747)


  Change in operating assets:









  Accounts receivable, trade



972,975




(11,009,813)


  Notes receivable



-




(928,801)


  Inventories



(3,361,143)




(1,887,064)


  Other receivables



(262,493)




(761,810)


  Advances to suppliers



5,117,601




(2,040,116)


  Other current assets



(849,209)




(779,191)


  Long term deposit



-




421,871


  Other noncurrent assets



92,785




251,938


  Change in operating liabilities:









  Accounts payable, trade



5,323,371




9,916,586


  Other payables and accrued liabilities



(654,911)




715,342


  Customer deposits



(2,925,130)




1,657,754


  Taxes payable



(45)




(242,908)


   Net cash provided by (used in) operating activities



2,579,557




(2,005,317)











CASH FLOWS FROM INVESTING ACTIVITIES:






  Purchase of equipment



(54,413)




(234,151)


  Increase in long-term deposits for land use right



(1,351,030)




-


  Additions to leasehold improvements



(26,619)




(253,163)


  Payments on construction-in-progress



(111,524)




-


    Net cash used in investing activities



(1,543,586)




(487,314)











CASH FLOWS FROM FINANCING ACTIVITIES:






  Proceeds from short-term bank loan



161,770




-


  Change in restricted cash



245,504




90,544


  Change in notes payable



(795,002)




2,328,686


  Change in other payables-related parties



879,958




(295,954)


    Net cash provided by financing activities



492,230




2,123,276











EFFECT OF EXCHANGE RATE ON CASH



244,420




44,100











INCREASE (DECREASE) IN CASH



1,772,621




(325,255)











CASH, beginning of period



4,524,094




3,833,216











CASH, end of period


$

6,296,715



$

3,507,961











SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:


  Cash paid for income taxes


$

12,797



$

-


  Transfer from construction-in-progress to leasehold improvement



-




2,703,428




SOURCE China Jo-Jo Drugstores, Inc.



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.